NCT07436702 Optimal Time for Reperfusion in Acute Pulmonary Embolism
| NCT ID | NCT07436702 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda ULSS 8 Berica |
| Condition | Pulmonary Embolism (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-11-25 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery). * Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines. * Provision of informed consent for the processing of personal data. Exclusion Criteria: * Age \< 18 years * Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded. * Inability to provide informed consent.
Contact & Investigator
Marco Zuin, MD MS
STUDY DIRECTOR
Department of Translational Medicine, University of Ferrara, Italy
Frequently Asked Questions
Who can join the NCT07436702 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Embolism (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436702 currently recruiting?
Yes, NCT07436702 is actively recruiting participants. Contact the research team at claudio.bilato@aulss8.veneto.it for enrollment information.
Where is the NCT07436702 trial being conducted?
This trial is being conducted at Milan, Italy, Monselice, Italy, Pavia, Italy, Perugia, Italy and 3 additional locations.
Who is sponsoring the NCT07436702 clinical trial?
NCT07436702 is sponsored by Azienda ULSS 8 Berica. The principal investigator is Marco Zuin, MD MS at Department of Translational Medicine, University of Ferrara, Italy. The trial plans to enroll 500 participants.